Quantum BioPharma Ltd QNTM.CD is expected to report results on November 12 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Quantum BioPharma Ltd is for a loss of $3.90 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Quantum BioPharma Ltd is 169.00, above its last closing price of $5.63.
This summary was machine generated November 9 at 00:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)